I think you have to put the cash burn into perspective that previously almost all IMU work was outsourced. At some point in the game the momentum must swing towards bringing some things in house. It also provides a long term advantage if they become assets in themselves. The manufacturing facility provides the drug we need for that trial so there is only an incremental cost outlay there in any case, but once the product is registered it becomes a cash generating machine.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.45M | |||
| Open | High | Low | Value | Volume |
| 26.5¢ | 27.0¢ | 26.0¢ | $342.7K | 1.284M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 59998 | 26.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 241705 | 10 |
View Market Depth
| Last trade - 16.10pm 12/08/2025 (20 minute delay) ? |
| IMU (ASX) Chart |